Is There a “Best” Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?

Article Tools EDITORIALS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1158 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870154 Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer? Stephen A. CannistraxStephen A. CannistraSearch for articles by this author Show More Beth Israel Deaconess Medical Center, Boston, MA https://doi.org/10.1200/JCO.2002.20.5.1158 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology